Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2014; 20(12): 3135-3145
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3135
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3135
Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights
Stephen L Chan, Winnie Yeo, Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China
Stephen L Chan, Winnie Yeo, State Key Laboratory in Oncology in South China, Hong Kong, China
Author contributions: Chan SL and Yeo W wrote the paper.
Correspondence to: Winnie Yeo, MD, FRCP, Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China. winnieyeo@cuhk.edu.hk
Telephone: +86-852-26322118 Fax: +86-852-26487097
Received: October 24, 2013
Revised: December 23, 2013
Accepted: January 19, 2014
Published online: March 28, 2014
Revised: December 23, 2013
Accepted: January 19, 2014
Published online: March 28, 2014
Core Tip
Core tip: This review article aims to provide an update and vision on the development of novel targeted agents for liver cancers. Recently released phase III clinical trial results as well as important future focus will be discussed.